Simulations Plus, Inc. (NASDAQ:SLP) Poised To Rebound After Short-Term Momentum Peak

Mixed technical momentum contrasts with a stretched fundamental picture: ample cash and strong free cash flow yield sit alongside a large reported net loss and compressed revenue. WMDST values the stock as under-valued.

Recent News

Aug. 25, 2025 — Hagens Berman announced an investor investigation after the company reported a sizeable net loss and an impairment charge; the firm questioned disclosures around the abrupt dismissal of auditor Grant Thornton. Aug. 13, 2025 — Bleichmar Fonti & Auld opened a securities investigation citing acquisition integration and internal-control concerns. Aug. 20, 2025 — Market coverage averaged a “Moderate Buy” consensus from seven analysts with a mean 12‑month price target near $26.50. Early August 2025 — Simulations Plus announced support for the FDA’s roadmap to reduce animal testing, highlighting its modeling and simulation capabilities and a new NAM-focused service package.

Technical Analysis

Directional indicators show an emerging trend: ADX at 24.57 signals a developing market direction rather than a strong trend, while DI+ near 27.99 recently peaked and reversed, producing a bearish directional read. DI- at 15.08 recently dipped then reversed higher, reinforcing the bearish tilt on directional indicators.

Momentum reads conflicted: MACD sits at 0.63 above its 0.48 signal line, yet the MACD recently peaked and reversed, indicating bearish momentum despite the current above‑signal position; expect momentum to require confirmation before a sustained move.

MRO reads negative at -6.87, which indicates the price sits below WMDST’s modeled target and therefore carries mean‑reversion potential toward the valuation target; the recent peak-and-reverse on the oscillator reduces immediate upside urgency but leaves room for reversion.

RSI at 53.04 recently peaked and reversed, suggesting loss of short-term strength but no overbought condition; the indicator places price near neutral momentum rather than extreme readings.

Price sits at $17.16, slightly above the 12‑day EMA $17.07 (increasing) and above the 20‑day average $16.67 and 50‑day average $15.38, which creates short‑term technical support, while the 200‑day average $23.09 remains a longer‑term resistance ceiling. SuperTrend lower band at $16.43 provides a clear nearby support reference. Bollinger band width remains contained between $14.09 and $19.25, implying limited immediate volatility expansion.

Volume at 245,991 undercuts short-, medium- and long‑term averages (10/50/200‑day average volumes all above ~450,000), which reduces conviction behind directional moves and increases the chance of range trading until volume normalizes.

 


Fundamental Analysis

Profitability and margins show mixed signals. The company reports $2,995,000 in EBIT and $5,313,000 in EBITDA; operating (EBIT) margin stands at 14.71%, up 21.65% QoQ and up 45.08% YoY, yet below the industry peer mean and median (industry peer mean EBIT margin 22.60%, median 30.79%). Gross margin sits at 63.998%, with a modest QoQ increase and a slight YoY decline.

Revenue and earnings: total revenue reached $20,363,000 while revenue growth measured -9.22% on the primary revenue metric provided. Reported net income shows a loss of $67,317,000 for the period ending 2025-05-31, while quarterly EPS came in at $0.45 versus an estimate of $0.25, producing an EPS surprise of +80% relative to the estimate.

Cash flow and balance sheet: free cash flow equals $7,054,000 with a free cash flow yield of 2.04%, which slightly exceeds the industry peer mean free cash flow yield of 1.46%; the company holds $28,450,000 in cash and short‑term investments and reports a current ratio of 5.11 (industry peer mean 4.45). Total debt remains negligible at $719,000, producing a debt‑to‑assets ratio near 0.54%, below the peer mean.

Returns and growth measures skew negative: return on equity equals -54.39% and return on assets equals -40.10%, reflecting the reported net loss and retained deficit of $33,683,000. Earnings-growth metrics present volatility: headline earningsGrowth registers positive in one measure but quarter‑to‑quarter and year‑over‑year earnings growth figures show material declines, underscoring uneven earnings dynamics.

Valuation context: P/E registers at 53.93 while forward P/E sits at 120.10; price‑to‑book stands at 2.79, below the industry peer mean P/B of 6.39. Enterprise value measures and an EV/R multiple near 15.60 place market pricing at a premium to near‑term revenue but the company’s substantial cash position and low leverage compress true enterprise exposure. WMDST values the stock as under‑valued based on the firm’s cash cushion, positive free cash flow yield relative to peers, and low net leverage, balanced against the reported net loss and depressed returns.

MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2025-05-31
REPORT DATE: 2025-07-14
NEXT REPORT DATE: 2025-09-29
CASH FLOW  Begin Period Cash Flow 11.0 M
 Operating Cash Flow 8.1 M
 Capital Expenditures -1.09 M
 Change In Working Capital 1.6 M
 Dividends Paid
 Cash Flow Delta 16.0 M
 End Period Cash Flow 26.9 M
 
INCOME STATEMENT REVENUE
 Total Revenue 20.4 M
 Forward Revenue -391.72 K
COSTS
 Cost Of Revenue 7.3 M
 Depreciation 2.3 M
 Depreciation and Amortization 2.3 M
 Research and Development 1.2 M
 Total Operating Expenses 17.4 M
PROFITABILITY
 Gross Profit 13.0 M
 EBITDA 5.3 M
 EBIT 3.0 M
 Operating Income 3.0 M
 Interest Income 170.0 K
 Interest Expense
 Net Interest Income 170.0 K
 Income Before Tax -74.04 M
 Tax Provision -6.73 M
 Tax Rate 9.085 %
 Net Income -67.32 M
 Net Income From Continuing Operations -67.32 M
EARNINGS
 EPS Estimate 0.25
 EPS Actual 0.45
 EPS Difference 0.20
 EPS Surprise 80.0 %
 Forward EPS 0.26
 
BALANCE SHEET ASSETS
 Total Assets 134.4 M
 Intangible Assets 73.6 M
 Net Tangible Assets 50.2 M
 Total Current Assets 51.8 M
 Cash and Short-Term Investments 28.4 M
 Cash 26.9 M
 Net Receivables 14.8 M
 Inventory
 Long-Term Investments 430.0 K
LIABILITIES
 Accounts Payable 1.7 M
 Short-Term Debt
 Total Current Liabilities 10.1 M
 Net Debt
 Total Debt 719.0 K
 Total Liabilities 10.6 M
EQUITY
 Total Equity 123.8 M
 Retained Earnings -33.68 M
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share 6.15
 Shares Outstanding 20.116 M
 Revenue Per-Share 1.01
VALUATION
 Market Capitalization 345.3 M
 Enterprise Value 317.6 M
 Enterprise Multiple 59.776
Enterprise Multiple QoQ -46.822 %
Enterprise Multiple YoY -76.959 %
Enterprise Multiple IPRWA high: 187.312
median: 129.932
mean: 124.276
SLP: 59.776
low: -61.072
 EV/R 15.596
CAPITAL STRUCTURE
 Asset To Equity 1.085
 Asset To Liability 12.698
 Debt To Capital 0.006
 Debt To Assets 0.005
Debt To Assets QoQ 35.443 %
Debt To Assets YoY 25.587 %
Debt To Assets IPRWA high: 0.603
mean: 0.052
median: 0.01
low: 0.008
SLP: 0.005
 Debt To Equity 0.006
Debt To Equity QoQ 38.333 %
Debt To Equity YoY 28.256 %
Debt To Equity IPRWA high: 1.265
mean: 0.086
median: 0.012
SLP: 0.006
low: -1.054
PRICE-BASED VALUATION
 Price To Book (P/B) 2.79
Price To Book QoQ -8.991 %
Price To Book YoY -45.952 %
Price To Book IPRWA high: 11.276
mean: 6.385
median: 6.06
SLP: 2.79
low: -6.059
 Price To Earnings (P/E) 53.925
Price To Earnings QoQ -72.003 %
Price To Earnings YoY -82.664 %
Price To Earnings IPRWA high: 163.345
median: 117.241
mean: 111.999
SLP: 53.925
low: -99.343
 PE/G Ratio 1.194
 Price To Sales (P/S) 16.958
Price To Sales QoQ -34.531 %
Price To Sales YoY -66.314 %
Price To Sales IPRWA high: 93.726
median: 49.584
mean: 48.374
SLP: 16.958
low: 0.843
FORWARD MULTIPLES
Forward P/E 120.097
Forward PE/G 2.659
Forward P/S -881.538
EFFICIENCY OPERATIONAL
 Operating Leverage -1.131
ASSET & SALES
 Asset Turnover Ratio 0.121
Asset Turnover Ratio QoQ 7.689 %
Asset Turnover Ratio YoY 26.449 %
Asset Turnover Ratio IPRWA high: 0.368
SLP: 0.121
mean: 0.112
median: 0.101
low: 0.0
 Receivables Turnover 1.302
Receivables Turnover Ratio QoQ -14.959 %
Receivables Turnover Ratio YoY -18.334 %
Receivables Turnover Ratio IPRWA high: 3.6
SLP: 1.302
mean: 1.164
median: 1.006
low: 0.882
 Inventory Turnover
Inventory Turnover Ratio QoQ
Inventory Turnover Ratio YoY
Inventory Turnover Ratio IPRWA
 Days Sales Outstanding (DSO) 70.07
CASH CYCLE
 Cash Conversion Cycle Days (CCC)
Cash Conversion Cycle Days QoQ
Cash Conversion Cycle Days YoY
Cash Conversion Cycle Days IPRWA
CAPITAL DEPLOYMENT
 Cash Conversion Ratio 0.489
 CapEx To Revenue -0.054
 CapEx To Depreciation -0.47
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital 123.8 M
 Net Invested Capital 123.8 M
 Invested Capital 123.8 M
 Net Tangible Assets 50.2 M
 Net Working Capital 41.6 M
LIQUIDITY
 Cash Ratio 2.808
 Current Ratio 5.111
Current Ratio QoQ 16.997 %
Current Ratio YoY -57.342 %
Current Ratio IPRWA high: 6.468
SLP: 5.111
median: 4.605
mean: 4.448
low: 0.014
 Quick Ratio
Quick Ratio QoQ
Quick Ratio YoY
Quick Ratio IPRWA
COVERAGE & LEVERAGE
 Debt To EBITDA 0.135
 Cost Of Debt 88.19 %
 Interest Coverage Ratio 4.076
Interest Coverage Ratio QoQ 10.435 %
Interest Coverage Ratio YoY 59.309 %
Interest Coverage Ratio IPRWA high: 23.544
median: 7.727
mean: 6.315
SLP: 4.076
low: -10.0
 Operating Cash Flow Ratio -6.202
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO) 14.068
DIVIDENDS
 Dividend Coverage Ratio
 Dividend Payout Ratio
 Dividend Rate
 Dividend Yield
PERFORMANCE GROWTH
 Asset Growth Rate -33.296 %
 Revenue Growth -9.223 %
Revenue Growth QoQ -149.755 %
Revenue Growth YoY -806.202 %
Revenue Growth IPRWA high: 33.14 %
median: 5.293 %
mean: 3.97 %
SLP: -9.223 %
low: -46.267 %
 Earnings Growth 45.161 %
Earnings Growth QoQ -96.774 %
Earnings Growth YoY -280.644 %
Earnings Growth IPRWA high: 675.0 %
SLP: 45.161 %
median: 13.218 %
mean: 7.874 %
low: -275.0 %
MARGINS
 Gross Margin 63.998 %
Gross Margin QoQ 9.363 %
Gross Margin YoY -10.479 %
Gross Margin IPRWA high: 96.642 %
median: 77.1 %
mean: 75.724 %
SLP: 63.998 %
low: 13.884 %
 EBIT Margin 14.708 %
EBIT Margin QoQ 21.654 %
EBIT Margin YoY 45.078 %
EBIT Margin IPRWA high: 37.363 %
median: 30.793 %
mean: 22.598 %
SLP: 14.708 %
low: -171.354 %
 Return On Sales (ROS) 14.708 %
Return On Sales QoQ 21.654 %
Return On Sales YoY 45.078 %
Return On Sales IPRWA high: 37.363 %
median: 30.793 %
mean: 22.721 %
SLP: 14.708 %
low: -171.354 %
CASH FLOW
 Free Cash Flow (FCF) 7.1 M
 Free Cash Flow Yield 2.043 %
Free Cash Flow Yield QoQ 150.675 %
Free Cash Flow Yield YoY 303.755 %
Free Cash Flow Yield IPRWA high: 4.882 %
median: 2.331 %
SLP: 2.043 %
mean: 1.455 %
low: -22.063 %
 Free Cash Growth 48.881 %
Free Cash Growth QoQ -115.428 %
Free Cash Growth YoY 380.828 %
Free Cash Growth IPRWA high: 297.281 %
SLP: 48.881 %
median: -37.992 %
mean: -44.797 %
low: -350.863 %
 Free Cash To Net Income -0.105
 Cash Flow Margin -308.545 %
 Cash Flow To Earnings 0.933
VALUE & RETURNS
 Economic Value Added 0.04
 Return On Assets (ROA) -40.095 %
Return On Assets QoQ -2698.509 %
Return On Assets YoY -2570.425 %
Return On Assets IPRWA high: 5.168 %
median: 3.021 %
mean: 2.338 %
low: -27.619 %
SLP: -40.095 %
 Return On Capital Employed (ROCE) 2.411 %
 Return On Equity (ROE) -0.544
Return On Equity QoQ -3452.959 %
Return On Equity YoY -3234.582 %
Return On Equity IPRWA high: 0.169
median: 0.037
mean: 0.027
low: -0.35
SLP: -0.544
 DuPont ROE -42.971 %
 Return On Invested Capital (ROIC) 2.2 %
Return On Invested Capital QoQ -119.061 %
Return On Invested Capital YoY -270.675 %
Return On Invested Capital IPRWA high: 8.024 %
median: 2.875 %
mean: 2.477 %
SLP: 2.2 %
low: -12.189 %

Six-Week Outlook

Expect range‑bound action with a modest downside bias unless momentum indicators reassert strength. Directional indicators currently favor sellers after DI+ peaked and reversed and DI- turned higher; MACD’s peak and reversal signals bearish momentum despite the MACD remaining above its signal line. Short‑term moving averages and the super trend at $16.43 provide technical support around current levels, while MRO’s negative reading implies upside potential toward WMDST’s valuation target if momentum recovers. Low trading volume increases the likelihood of choppy swings rather than sustained directional moves over the next six weeks; monitor shifts in MACD and volume for confirmation of a directional breakout or renewed consolidation.

About Simulations Plus, Inc.

Simulations Plus, Inc. (NASDAQ:SLP) develops advanced software solutions for drug discovery and development, leveraging artificial intelligence and machine learning technologies. The company operates through its Software and Services segments, offering a range of products designed to simulate and predict molecular properties and interactions. Key offerings include GastroPlus, which models the absorption and interaction of compounds in humans and animals, as well as DDDPlus and MembranePlus simulation tools. Simulations Plus also provides mechanistic and mathematical model-based products such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym. These products assist in understanding complex biological systems and drug interactions. The company offers the ADMET Predictor, a chemistry-based program that predicts molecular properties from structures, and the MedChem Designer for molecular design and analysis. Additionally, Simulations Plus delivers consulting services in clinical pharmacology, including population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, and clinical trial simulations. Their consulting services support regulatory submissions and early drug discovery efforts. The company’s clientele spans pharmaceutical, biotechnology, agrochemical, cosmetics, and food industries, as well as academic and regulatory institutions. Established in 1996, Simulations Plus is headquartered in Lancaster, California.



© 2025 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.